Drug intelligence / Profile preview

MIC-4578

Development stage: Preclinical
Lead developer: Micar Innovation
Modality: Small Molecules

Overview

MIC-4578 is a small molecule drug candidate developed by Micar Innovation Micar21. It acts as an inhibitor of glycine transporter 2 (GlyT2), a sodium- and chloride-dependent transporter responsible for the reuptake of glycine at inhibitory synapses in the central nervous system. By inhibiting GlyT2, MIC-4578 is designed to modulate glycinergic neurotransmission, which may play a role in the management of chronic pain. The compound is currently in preclinical development for nervous system diseases, with its primary indication being chronic pain[1][9].

Other names: MIC4578MIC-4578MIC 4578

Targets

GlyT2 (Glycine transporter type 2)

Beyond the preview

Go deeper on MIC-4578.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MIC-4578.

Explore the full profile